| Clinical characteristics of Covid-19 in New York city P Goyal, JJ Choi, LC Pinheiro, EJ Schenck, R Chen, A Jabri, MJ Satlin, ... New England Journal of Medicine 382 (24), 2372-2374, 2020 | 2760 | 2020 |
| Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy RM Gulick, JW Mellors, D Havlir, JJ Eron, C Gonzalez, D McMahon, ... New England Journal of Medicine 337 (11), 734-739, 1997 | 2490 | 1997 |
| Severe covid-19 DA Berlin, RM Gulick, FJ Martinez New England Journal of Medicine 383 (25), 2451-2460, 2020 | 1784 | 2020 |
| Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial PB Gilbert, DC Montefiori, AB McDermott, Y Fong, D Benkeser, W Deng, ... Science 375 (6576), 43-50, 2022 | 1091 | 2022 |
| Maraviroc for previously treated patients with R5 HIV-1 infection RM Gulick, J Lalezari, J Goodrich, N Clumeck, E DeJesus, A Horban, ... New England Journal of Medicine 359 (14), 1429-1441, 2008 | 940 | 2008 |
| Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 M Caskey, F Klein, JCC Lorenzi, MS Seaman, AP West Jr, N Buckley, ... Nature 522 (7557), 487-491, 2015 | 858 | 2015 |
| Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study DW Haas, HJ Ribaudo, RB Kim, C Tierney, GR Wilkinson, RM Gulick, ... Aids 18 (18), 2391-2400, 2004 | 804 | 2004 |
| Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection RM Gulick, HJ Ribaudo, CM Shikuma, S Lustgarten, KE Squires, ... New England Journal of Medicine 350 (18), 1850-1861, 2004 | 714 | 2004 |
| Cabotegravir for HIV prevention in cisgender men and transgender women RJ Landovitz, D Donnell, ME Clement, B Hanscom, L Cottle, L Coelho, ... New England Journal of Medicine 385 (7), 595-608, 2021 | 665 | 2021 |
| Early versus standard antiretroviral therapy for HIV-infected adults in Haiti P Severe, MA Jean Juste, A Ambroise, L Eliacin, C Marchand, S Apollon, ... New England Journal of Medicine 363 (3), 257-265, 2010 | 543 | 2010 |
| HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption JF Scheid, JA Horwitz, Y Bar-On, EF Kreider, CL Lu, JCC Lorenzi, ... Nature 535 (7613), 556-560, 2016 | 522 | 2016 |
| Combination therapy with anti-HIV-1 antibodies maintains viral suppression P Mendoza, H Gruell, L Nogueira, JA Pai, AL Butler, K Millard, ... Nature 561 (7724), 479-484, 2018 | 509 | 2018 |
| Antibody 10-1074 suppresses viremia in HIV-1-infected individuals M Caskey, T Schoofs, H Gruell, A Settler, T Karagounis, EF Kreider, ... Nature medicine 23 (2), 185-191, 2017 | 496 | 2017 |
| Antiretroviral therapy in a thousand patients with AIDS in Haiti P Severe, P Leger, M Charles, F Noel, G Bonhomme, G Bois, E George, ... New England Journal of Medicine 353 (22), 2325-2334, 2005 | 362 | 2005 |
| Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals DB Clifford, S Evans, Y Yang, EP Acosta, K Goodkin, K Tashima, ... Annals of internal medicine 143 (10), 714-721, 2005 | 344 | 2005 |
| Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211 RM Gulick, Z Su, C Flexner, MD Hughes, PR Skolnik, TJ Wilkin, R Gross, ... The Journal of infectious diseases 196 (2), 304-312, 2007 | 316 | 2007 |
| ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results RL Murphy, S Brun, C Hicks, JJ Eron, R Gulick, M King, AC White Jr, ... Aids 15 (1), F1-F9, 2001 | 305 | 2001 |
| Three-vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial RM Gulick, HJ Ribaudo, CM Shikuma, C Lalama, BR Schackman, ... Jama 296 (7), 769-781, 2006 | 292 | 2006 |
| Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up RM Gulick, JW Mellors, D Havlir, JJ Eron, C Gonzalez, D McMahon, ... Jama 280 (1), 35-41, 1998 | 285 | 1998 |
| Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure R Paredes, CM Lalama, HJ Ribaudo, BR Schackman, C Shikuma, ... The Journal of infectious diseases 201 (5), 662-671, 2010 | 265 | 2010 |
